Securecell

Executive Summary

Securecell is a Swiss life sciences technology company specializing in bioprocess automation and medtech innovations. Since its founding in 2004, the company has developed two distinct product lines: the Lucullus SCADA platform and automated sampling systems for biotech, and the Seraccess® technology for continuous blood parameter monitoring and an artificial pancreas device. In biotech, Securecell's solutions help optimize bioprocessing through real-time data acquisition and control, serving research labs and production facilities. In medtech, its Seraccess® system aims to improve critical care by enabling frequent, minimally invasive blood analysis, while the artificial pancreas project targets automated insulin delivery for diabetes management. The company's dual focus on process automation and patient monitoring positions it as a versatile innovation partner in both industrial and clinical settings. With over 20 years of history, Securecell has built a solid reputation in the bioprocess market, but its medtech ventures are still in earlier stages and represent significant growth potential. The company operates from Schlieren, Switzerland, and remains privately held, with no disclosed funding rounds or valuation. Its ability to bridge lab automation and medical diagnostics could drive future expansion, especially as demand rises for digital health solutions and continuous monitoring in intensive care. Nonetheless, the medtech products face regulatory hurdles and competition, while the biotech segment provides a stable revenue base. Overall, Securecell is a niche player with promising technology in both sectors, but its private status limits visibility into financial performance and milestones.

Upcoming Catalysts (preview)

• Q4 2026CE Mark or FDA clearance for Seraccess continuous blood monitoring system50% success
• Q2 2026Release of next-generation Lucullus SCADA software with AI-enhanced process control70% success
• Q3 2026Partnership agreement with a major biopharma for automated sampling integration40% success